Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives
Tóm tắt
Từ khóa
Tài liệu tham khảo
Mattick, 2010, A global view of genomic information–moving beyond the gene and the master regulator, Trends Genet, 26, 21, 10.1016/j.tig.2009.11.002
Dunham, 2012, An integrated encyclopedia of DNA elements in the human genome, Nature, 489, 57, 10.1038/nature11247
Hardison, 2012, Genome-wide epigenetic data facilitate understanding of disease susceptibility association studies, J Biol Chem, 287, 30932, 10.1074/jbc.R112.352427
Hoffman, 2013, Integrative annotation of chromatin elements from ENCODE data, Nucleic Acids Res, 41, 827, 10.1093/nar/gks1284
Stunnenberg, 2016, The international human epigenome consortium: a blueprint for scientific collaboration and discovery, Cell, 167, 1145, 10.1016/j.cell.2016.11.007
Stunnenberg, 2016, The international human epigenome consortium: a blueprint for scientific collaboration and discovery, Cell, 167, 1897., 10.1016/j.cell.2016.12.002
Bujold, 2016, The International human epigenome consortium data portal, Cell Syst, 3, 496, 10.1016/j.cels.2016.10.019
Chen, 2016, Genetic drivers of epigenetic and transcriptional variation in human immune cells, Cell, 167, 1398, 10.1016/j.cell.2016.10.026
Edfors, 2016, Gene-specific correlation of RNA and protein levels in human cells and tissues, Mol Syst Biol, 12, 883., 10.15252/msb.20167144
Thum, 2015, Long noncoding RNAs and microRNAs in cardiovascular pathophysiology, Circ Res, 116, 751, 10.1161/CIRCRESAHA.116.303549
Philippen, 2015, Antisense MicroRNA therapeutics in cardiovascular disease: Quo Vadis?, Mol Ther, 23, 1810, 10.1038/mt.2015.133
Creemers, 2016, Function and therapeutic potential of noncoding rnas in cardiac fibrosis, Circ Res, 118, 108, 10.1161/CIRCRESAHA.115.305242
Leistner, 2016, Transcoronary gradients of vascular miRNAs and coronary atherosclerotic plaque characteristics, Eur Heart J, 37, 1738, 10.1093/eurheartj/ehw047
Nampoothiri, 2016, ISCHEMIRs: finding a way through the obstructed cerebral arteries, Curr Drug Targets, 17, 800, 10.2174/1389450116666150518102404
Welten, 2016, The multifactorial nature of microRNAs in vascular remodelling, Cardiovasc Res, 110, 6, 10.1093/cvr/cvw039
Das, 2015, Extracellular vesicle microRNA transfer in cardiovascular disease, Cardiovasc Pathol, 24, 199, 10.1016/j.carpath.2015.04.007
Rohde, 2015, A universal aptamer chimera for the delivery of functional microRNA-126, Nucleic Acid Ther, 25, 141, 10.1089/nat.2014.0501
Hartmann, 2015, Chemokines and microRNAs in atherosclerosis, Cell Mol Life Sci, 72, 3253, 10.1007/s00018-015-1925-z
Nazari-Jahantigh, 2015, MicroRNA-specific regulatory mechanisms in atherosclerosis, J Mol Cell Cardiol, 89, 35, 10.1016/j.yjmcc.2014.10.021
Kumar, 2014, Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs, Arterioscler Thromb Vasc Biol, 34, 2206, 10.1161/ATVBAHA.114.303425
Boon, 2013, MicroRNA-34a regulates cardiac ageing and function, Nature, 495, 107, 10.1038/nature11919
Seeger, 2013, Immunosenescence-associated microRNAs in age and heart failure, Eur J Heart Fail, 15, 385, 10.1093/eurjhf/hfs184
Jakob, 2012, Loss of angiomiR-126 and 130a in angiogenic early outgrowth cells from patients with chronic heart failure: role for impaired in vivo neovascularization and cardiac repair capacity, Circulation, 126, 2962, 10.1161/CIRCULATIONAHA.112.093906
Hergenreider, 2012, Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs, Nat Cell Biol, 14, 249, 10.1038/ncb2441
Boon, 2012, Atheroprotective mechanisms of shear stress-regulated microRNAs, Thromb Haemost, 108, 616, 10.1160/TH12-07-0491
Jakob, 2016, Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction, Eur Heart J, 10.1093/eurheartj/ehw563
Wu, 2014, RNAi therapies: drugging the undruggable, Sci Transl Med, 6, 240ps7., 10.1126/scitranslmed.3008362
Maheshwari, 2015, Nanocarriers assisted siRNA gene therapy for the management of cardiovascular disorders, Curr Pharm Des, 21, 4427, 10.2174/138161282130151007150300
Fire, 1998, Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391, 806, 10.1038/35888
Khvorova, 2017, The chemical evolution of oligonucleotide therapies of clinical utility, Nat Biotechnol, 35, 238, 10.1038/nbt.3765
Crooke, 2017, Cellular uptake and trafficking of antisense oligonucleotides, Nat Biotechnol, 35, 230, 10.1038/nbt.3779
Zamore, 2006, RNA interference: big applause for silencing in Stockholm, Cell, 127, 1083, 10.1016/j.cell.2006.12.001
Suckau, 2009, Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy, Circulation, 119, 1241, 10.1161/CIRCULATIONAHA.108.783852
Hulot, 2016, Gene therapy for the treatment of heart failure: promise postponed, Eur Heart J, 37, 1651, 10.1093/eurheartj/ehw019
Majmudar, 2013, Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice, Circulation, 127, 2038, 10.1161/CIRCULATIONAHA.112.000116
Burroughs, 2014, New perspectives on the diversification of the RNA interference system: insights from comparative genomics and small RNA sequencing, Wiley Interdiscip Rev RNA, 5, 141, 10.1002/wrna.1210
Thum, 2008, MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts, Nature, 456, 980, 10.1038/nature07511
van Rooij, 2012, Developing microRNA therapeutics, Circ Res, 110, 496, 10.1161/CIRCRESAHA.111.247916
Abdellatif, 2012, Differential expression of microRNAs in different disease states, Circ Res, 110, 638, 10.1161/CIRCRESAHA.111.247437
Zampetaki, 2012, MicroRNAs in vascular and metabolic disease, Circ Res, 110, 508, 10.1161/CIRCRESAHA.111.247445
Boettger, 2012, A new level of complexity: the role of microRNAs in cardiovascular development, Circ Res, 110, 1000, 10.1161/CIRCRESAHA.111.247742
Mayr, 2013, MicroRNAs within the continuum of postgenomics biomarker discovery, Arterioscler Thromb Vasc Biol, 33, 206, 10.1161/ATVBAHA.112.300141
Ho, 2016, Bioengineering of noncoding RNAs for research agents and therapeutics, Wiley Interdiscip Rev RNA, 7, 186, 10.1002/wrna.1324
Chen, 2015, A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications, Nucleic Acids Res, 43, 3857, 10.1093/nar/gkv228
Snead, 2010, Biogenesis and function of endogenous and exogenous siRNAs, Wiley Interdiscip Rev RNA, 1, 117, 10.1002/wrna.14
Zong, 2016, Natural antisense RNA promotes 3' end processing and maturation of MALAT1 lncRNA, Nucleic Acids Res, 44, 2898, 10.1093/nar/gkw047
Chen, 2015, Biogenesis, identification, and function of exonic circular RNAs, Wiley Interdiscip Rev RNA, 6, 563, 10.1002/wrna.1294
Housman, 2016, Methods for distinguishing between protein-coding and long noncoding RNAs and the elusive biological purpose of translation of long noncoding RNAs, Biochim Biophys Acta, 1859, 31, 10.1016/j.bbagrm.2015.07.017
Gloss, 2016, The specificity of long noncoding RNA expression, Biochim Biophys Acta, 1859, 16, 10.1016/j.bbagrm.2015.08.005
Kashi, 2016, Discovery and functional analysis of lncRNAs: Methodologies to investigate an uncharacterized transcriptome, Biochim Biophys Acta, 1859, 3, 10.1016/j.bbagrm.2015.10.010
Derrien, 2012, The GENCODE v7 catalog of human long noncoding RNAs: analysis of their gene structure, evolution, and expression, Genome Res, 22, 1775, 10.1101/gr.132159.111
Harrow, 2012, GENCODE: the reference human genome annotation for The ENCODE Project, Genome Res, 22, 1760, 10.1101/gr.135350.111
Boon, 2016, Long noncoding RNAs: from clinical genetics to therapeutic targets?, J Am Coll Cardiol, 67, 1214, 10.1016/j.jacc.2015.12.051
Hirose, 2016, Clues to long noncoding RNA taxonomy, Biochim Biophys Acta, 1859, 1, 10.1016/j.bbagrm.2015.11.011
Ruhle, 2016, Long non-coding RNA databases in cardiovascular research, Genomics Proteomics Bioinformatics, 14, 191, 10.1016/j.gpb.2016.03.001
Nakagawa, 2016, Lessons from reverse-genetic studies of lncRNAs, Biochim Biophys Acta, 1859, 177, 10.1016/j.bbagrm.2015.06.011
Ulitsky, 2013, lincRNAs: genomics, evolution, and mechanisms, Cell, 154, 26, 10.1016/j.cell.2013.06.020
Batista, 2013, Long noncoding RNAs: cellular address codes in development and disease, Cell, 152, 1298, 10.1016/j.cell.2013.02.012
Pefanis, 2015, RNA exosome-regulated long non-coding RNA transcription controls super-enhancer activity, Cell, 161, 774, 10.1016/j.cell.2015.04.034
Necsulea, 2014, The evolution of lncRNA repertoires and expression patterns in tetrapods, Nature, 505, 635, 10.1038/nature12943
Fiedler, 2015, Development of long noncoding RNA-based strategies to modulate tissue vascularization, J Am Coll Cardiol, 66, 2005, 10.1016/j.jacc.2015.07.081
Michalik, 2014, The long noncoding RNA MALAT1 regulates endothelial cell function and vessel growth, Circ Res, 114, 1389, 10.1161/CIRCRESAHA.114.303265
Gast, 2016, Long noncoding RNA MALAT1-derived mascRNA is involved in cardiovascular innate immunity, J Mol Cell Biol, 8, 178, 10.1093/jmcb/mjw003
Lima, 2016, RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery, Nucleic Acids Res, 10.1093/nar/gkw065
Wilusz, 2016, Long noncoding RNAs: Re-writing dogmas of RNA processing and stability, Biochim Biophys Acta, 1859, 128, 10.1016/j.bbagrm.2015.06.003
Wilusz, 2008, 3' end processing of a long nuclear-retained noncoding RNA yields a tRNA-like cytoplasmic RNA, Cell, 135, 919, 10.1016/j.cell.2008.10.012
Klattenhoff, 2013, Braveheart, a long noncoding RNA required for cardiovascular lineage commitment, Cell, 152, 570, 10.1016/j.cell.2013.01.003
Smith, 2015, Genome-wide association studies of late-onset cardiovascular disease, J Mol Cell Cardiol, 83, 131, 10.1016/j.yjmcc.2015.04.004
Smith, 2015, Identifying functional noncoding variants from genome-wide association studies for cardiovascular disease and related traits, Curr Opin Lipidol, 26, 120, 10.1097/MOL.0000000000000158
Congrains, 2012, Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B, Atherosclerosis, 220, 449, 10.1016/j.atherosclerosis.2011.11.017
Pasmant, 2011, ANRIL, a long, noncoding RNA, is an unexpected major hotspot in GWAS, FASEB J, 25, 444, 10.1096/fj.10-172452
Newton-Cheh, 2009, Genome-wide association study identifies eight loci associated with blood pressure, Nat Genet, 41, 666, 10.1038/ng.361
Craig, 2011, Assessing and managing risk when sharing aggregate genetic variant data, Nat Rev Genet, 12, 730, 10.1038/nrg3067
Manolio, 2013, Bringing genome-wide association findings into clinical use, Nat Rev Genet, 14, 549, 10.1038/nrg3523
MacArthur, 2014, Guidelines for investigating causality of sequence variants in human disease, Nature, 508, 469, 10.1038/nature13127
Civelek, 2014, Systems genetics approaches to understand complex traits, Nat Rev Genet, 15, 34, 10.1038/nrg3575
Spisak, 2015, CAUSEL: an epigenome- and genome-editing pipeline for establishing function of noncoding GWAS variants, Nat Med, 10.1038/nm.3975
Yang, 2014, Deep RNA sequencing reveals dynamic regulation of myocardial noncoding RNAs in failing human heart and remodeling with mechanical circulatory support, Circulation, 129, 1009, 10.1161/CIRCULATIONAHA.113.003863
Bjorkegren, 2015, Genome-wide significant loci: how important are they? Systems genetics to understand heritability of coronary artery disease and other common complex disorders, J Am Coll Cardiol, 65, 830
Wahlquist, 2014, Inhibition of miR-25 improves cardiac contractility in the failing heart, Nature, 508, 531, 10.1038/nature13073
Bell, 2014, Identification and initial functional characterization of a human vascular cell-enriched long noncoding RNA, Arterioscler Thromb Vasc Biol, 34, 1249, 10.1161/ATVBAHA.114.303240
Thum, 2014, The smooth long noncoding RNA SENCR, Arterioscler Thromb Vasc Biol, 34, 1124, 10.1161/ATVBAHA.114.303504
Meyer, 2016, Essential role for premature senescence of myofibroblasts in myocardial fibrosis, J Am Coll Cardiol, 67, 2018, 10.1016/j.jacc.2016.02.047
Jiang, 2014, Expression profiling of long noncoding RNAs and the dynamic changes of lncRNA-NR024118 and Cdkn1c in angiotensin II-treated cardiac fibroblasts, Int J Clin Exp Pathol, 7, 1325
Thum, 2014, Noncoding RNAs and myocardial fibrosis, Nat Rev Cardiol, 11, 655, 10.1038/nrcardio.2014.125
Pan, 2012, MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway, Circulation, 126, 840, 10.1161/CIRCULATIONAHA.112.094524
Cardin, 2012, Role for MicroRNA-21 in atrial profibrillatory fibrotic remodeling associated with experimental postinfarction heart failure, Circ Arrhythm Electrophysiol, 5, 1027, 10.1161/CIRCEP.112.973214
Jiang, 2015, Losartan reverses the down-expression of long noncoding RNA-NR024118 and Cdkn1c induced by angiotensin II in adult rat cardiac fibroblasts, Pathol Biol (Paris), 63, 122, 10.1016/j.patbio.2015.04.001
Tank, 2014, Single-target RNA interference for the blockade of multiple interacting proinflammatory and profibrotic pathways in cardiac fibroblasts, J Mol Cell Cardiol, 66, 141, 10.1016/j.yjmcc.2013.11.004
Goedeke, 2015, MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels, Nat Med, 10.1038/nm.3949
Zhou, 2014, High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells, Nature, 509, 487, 10.1038/nature13166
Hullinger, 2012, Inhibition of miR-15 protects against cardiac ischemic injury, Circ Res, 110, 71, 10.1161/CIRCRESAHA.111.244442
Bernardo, 2012, Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function, Proc Natl Acad Sci U S A, 109, 17615, 10.1073/pnas.1206432109
Yin, 2012, Vascular endothelial cell-specific microRNA-15a inhibits angiogenesis in hindlimb ischemia, J Biol Chem, 287, 27055, 10.1074/jbc.M112.364414
Bonauer, 2009, MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice, Science, 324, 1710, 10.1126/science.1174381
Chamorro-Jorganes, 2016, VEGF-induced expression of miR-17-92 cluster in endothelial cells is mediated by ERK/ELK1 activation and regulates angiogenesis, Circ Res, 118, 38, 10.1161/CIRCRESAHA.115.307408
Hinkel, 2013, Inhibition of microRNA-92a protects against ischemia/reperfusion injury in a large-animal model, Circulation, 128, 1066, 10.1161/CIRCULATIONAHA.113.001904
Wu, 2011, Flow-dependent regulation of Kruppel-like factor 2 is mediated by MicroRNA-92a, Circulation, 124, 633, 10.1161/CIRCULATIONAHA.110.005108
Icli, 2013, MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling, Circ Res, 113, 1231, 10.1161/CIRCRESAHA.113.301780
Li, 2014, Mitofusin 1 is negatively regulated by microRNA 140 in cardiomyocyte apoptosis, Mol Cell Biol, 34, 1788, 10.1128/MCB.00774-13
Hu, 2010, MicroRNA-210 as a novel therapy for treatment of ischemic heart disease, Circulation, 122(11 Suppl), S124, 10.1161/CIRCULATIONAHA.109.928424
Qian, 2011, miR-24 inhibits apoptosis and represses Bim in mouse cardiomyocytes, J Exp Med, 208, 549, 10.1084/jem.20101547
Fiedler, 2011, MicroRNA-24 regulates vascularity after myocardial infarction, Circulation, 124, 720, 10.1161/CIRCULATIONAHA.111.039008
Meloni, 2013, Local inhibition of microRNA-24 improves reparative angiogenesis and left ventricle remodeling and function in mice with myocardial infarction, Mol Ther, 21, 1390, 10.1038/mt.2013.89
van Rooij, 2007, Control of stress-dependent cardiac growth and gene expression by a microRNA, Science, 316, 575, 10.1126/science.1139089
Thum, 2007, MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure, Circulation, 116, 258, 10.1161/CIRCULATIONAHA.107.687947
Corsten, 2012, MicroRNA profiling identifies microRNA-155 as an adverse mediator of cardiac injury and dysfunction during acute viral myocarditis, Circ Res, 111, 415, 10.1161/CIRCRESAHA.112.267443
Heymans, 2016, The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy, J Am Coll Cardiol, 68, 2348, 10.1016/j.jacc.2016.09.937
Yan, 2016, Inhibition of microRNA-155 ameliorates experimental autoimmune myocarditis by modulating Th17/Treg immune response, J Mol Med (Berl), 10.1007/s00109-016-1414-3
Zhang, 2016, Silencing MicroRNA-155 attenuates cardiac injury and dysfunction in viral myocarditis via promotion of M2 phenotype polarization of macrophages, Sci Rep, 6, 22613., 10.1038/srep22613
Liu, 2013, MicroRNA-21 and -146b are involved in the pathogenesis of murine viral myocarditis by regulating TH-17 differentiation, Arch Virol, 158, 1953, 10.1007/s00705-013-1695-6
Schober, 2015, MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis, Nat Rev Cardiol, 12, 361, 10.1038/nrcardio.2015.38
Schober, 2016, MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis, Nat Rev Cardiol, 13, 120., 10.1038/nrcardio.2015.190
Santovito, 2015, Small but smart: MicroRNAs orchestrate atherosclerosis development and progression, Biochim Biophys Acta
Schober, 2014, MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1, Nat Med, 20, 368, 10.1038/nm.3487
Zernecke, 2009, Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection, Sci Signal, 2, ra81., 10.1126/scisignal.2000610
Lovren, 2012, MicroRNA-145 targeted therapy reduces atherosclerosis, Circulation, 126, S81, 10.1161/CIRCULATIONAHA.111.084186
Sun, 2014, Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice, Circ Res, 114, 32, 10.1161/CIRCRESAHA.113.302089
Loyer, 2014, Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice, Circ Res, 114, 434, 10.1161/CIRCRESAHA.114.302213
Son, 2013, The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis, Nat Commun, 4, 3000., 10.1038/ncomms4000
Nazari-Jahantigh, 2012, MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages, J Clin Invest, 122, 4190, 10.1172/JCI61716
Du, 2014, MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice, Arterioscler Thromb Vasc Biol, 34, 759, 10.1161/ATVBAHA.113.302701
Wei, 2013, The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis, Circulation, 127, 1609, 10.1161/CIRCULATIONAHA.112.000736
Price, 2014, Relevance of microRNA in metabolic diseases, Crit Rev Clin Lab Sci, 51, 305, 10.3109/10408363.2014.937522
Frank-Kamenetsky, 2008, Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates, Proc Natl Acad Sci U S A, 105, 11915, 10.1073/pnas.0805434105
Fitzgerald, 2014, Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial, Lancet, 383, 60, 10.1016/S0140-6736(13)61914-5
Fitzgerald, 2017, A highly durable RNAi therapeutic inhibitor of PCSK9, N Engl J Med, 376, 41, 10.1056/NEJMoa1609243
Lindholm, 2012, PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates, Mol Ther, 20, 376, 10.1038/mt.2011.260
Tsimikas, 2015, Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study, Lancet, 10.1016/S0140-6736(15)61252-1
Stroes, 2015, A sense of excitement for a specific Lp(a)-lowering therapy, Lancet, 386, 1427, 10.1016/S0140-6736(15)60638-9
Farhan, 2015, Trial watch: antisenses working overtime in lipids, Nat Rev Endocrinol, 11, 574, 10.1038/nrendo.2015.146
Coelho, 2013, Safety and efficacy of RNAi therapy for transthyretin amyloidosis, N Engl J Med, 369, 819, 10.1056/NEJMoa1208760
Thi, 2015, Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature, 521, 362, 10.1038/nature14442
Daniel, 2014, Inhibition of miR-92a improves re-endothelialization and prevents neointima formation following vascular injury, Cardiovasc Res, 103, 564, 10.1093/cvr/cvu162
Gupta, 2009, Silencing the myotrophin gene by RNA interference leads to the regression of cardiac hypertrophy, Am J Physiol Heart Circ Physiol, 297, H627, 10.1152/ajpheart.00294.2009
Zhang, 2012, Induction of alloimmune tolerance in heart transplantation through gene silencing of TLR adaptors, Am J Transplant, 12, 2675, 10.1111/j.1600-6143.2012.04196.x
Guo, 2013, Lentivirus-mediated RNA interference of chymase increases the plaque stability in atherosclerosis in vivo, Exp Mol Pathol, 10.1016/j.yexmp.2013.05.005
Wittrup, 2015, Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown, Nat Biotechnol, 33, 870, 10.1038/nbt.3298
Torrado, 2011, Targeted gene-silencing reveals the functional significance of myocardin signaling in the failing heart, PLoS One, 6, e26392., 10.1371/journal.pone.0026392
Matsa, 2013, Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes, Eur Heart J
Frazier, 2015, Scientific and Regulatory policy committee points-to-consider paper*: drug-induced vascular injury associated with nonsmall molecule therapeutics in preclinical development: part I. biotherapeutics, Toxicol Pathol, 43, 915, 10.1177/0192623315570340
Engelhardt, 2015, Scientific and regulatory policy committee points-to-consider paper*: drug-induced vascular injury associated with nonsmall molecule therapeutics in preclinical development: part 2. antisense oligonucleotides, Toxicol Pathol, 43, 935, 10.1177/0192623315570341
Lam, 2015, siRNA Versus miRNA as Therapeutics for Gene Silencing, Mol Ther Nucleic Acids, 4, e252., 10.1038/mtna.2015.23
Wittrup, 2015, Knocking down disease: a progress report on siRNA therapeutics, Nat Rev Genet, 16, 543, 10.1038/nrg3978
Townshend, 2015, High-throughput cellular RNA device engineering, Nat Methods, 12, 989, 10.1038/nmeth.3486
Blattmann, 2013, RNAi-based functional profiling of loci from blood lipid genome-wide association studies identifies genes with cholesterol-regulatory function, PLoS Genet, 9, e1003338., 10.1371/journal.pgen.1003338
Gadde, 2016, Nanomedicine meets microRNA: current advances in RNA-based nanotherapies for atherosclerosis, Arterioscler Thromb Vasc Biol, 36, e73, 10.1161/ATVBAHA.116.307481
Turnbull, 2016, Myocardial delivery of lipidoid nanoparticle carrying modRNA induces rapid and transient expression, Mol Ther, 24, 66, 10.1038/mt.2015.193
Lorenzer, 2015, Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics, J Control Release, 203, 1, 10.1016/j.jconrel.2015.02.003
Grijalvo, 2014, Oligonucleotide delivery: a patent review (2010–2013), Expert Opin Ther Pat, 10.1517/13543776.2014.915944
Ludwig, 2013, Rapid binding of electrostatically stabilized iron oxide nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans, Basic Res Cardiol, 108, 328., 10.1007/s00395-013-0328-2
Khvorova, 2017, Oligonucleotide therapeutics— a new class of cholesterol-lowering drugs, N Engl J Med, 376, 4, 10.1056/NEJMp1614154
Elbashir, 2001, Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, Nature, 411, 494, 10.1038/35078107
Haraguchi, 2012, A potent 2'-O-methylated RNA-based microRNA inhibitor with unique secondary structures, Nucleic Acids Res, 40, e58., 10.1093/nar/gkr1317
Krutzfeldt, 2005, Silencing of microRNAs in vivo with ‘antagomirs’, Nature, 438, 685, 10.1038/nature04303
Grunweller, 2003, Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA, Nucleic Acids Res, 31, 3185, 10.1093/nar/gkg409
Ebert, 2007, MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells, Nat Methods, 4, 721, 10.1038/nmeth1079
Sayed, 2008, MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths, Mol Biol Cell, 19, 3272, 10.1091/mbc.e08-02-0159
Gambari, 2011, Targeting microRNAs involved in human diseases: a novel approach for modification of gene expression and drug development, Biochem Pharmacol, 82, 1416, 10.1016/j.bcp.2011.08.007
Goldgraben, 2016, Double-stranded microRNA mimics can induce length- and passenger strand-dependent effects in a cell type-specific manner, RNA, 22, 193, 10.1261/rna.054072.115
Bar, 2016, Long noncoding RNAs in cardiovascular pathology, diagnosis, and therapy, Circulation, 134, 1484, 10.1161/CIRCULATIONAHA.116.023686
Devaux, 2015, Long noncoding RNAs in cardiac development and ageing, Nat Rev Cardiol, 12, 415, 10.1038/nrcardio.2015.55
Lorenzen, 2016, Long noncoding RNAs in kidney and cardiovascular diseases, Nat Rev Nephrol, 12, 360, 10.1038/nrneph.2016.51
Rayner, 2016, Long noncoding RNAs in the heart: the regulatory roadmap of cardiovascular development and disease, Circ Cardiovasc Genet, 9, 101, 10.1161/CIRCGENETICS.116.001413
Liu, 2016, The H19 long noncoding RNA is a novel negative regulator of cardiomyocyte hypertrophy, Cardiovasc Res, 111, 56, 10.1093/cvr/cvw078
Voellenkle, 2016, Implication of Long noncoding RNAs in the endothelial cell response to hypoxia revealed by RNA-sequencing, Sci Rep, 6, 24141., 10.1038/srep24141
Rinn, 2012, Genome regulation by long noncoding RNAs, Annu Rev Biochem, 81, 145, 10.1146/annurev-biochem-051410-092902
Mendell, 2016, Targeting a Long Noncoding RNA in Breast Cancer, N Engl J Med, 374, 2287, 10.1056/NEJMcibr1603785
Sanbonmatsu, 2016, Towards structural classification of long non-coding RNAs, Biochim Biophys Acta, 1859, 41, 10.1016/j.bbagrm.2015.09.011
Blythe, 2016, The ins and outs of lncRNA structure: how, why and what comes next?, Biochim Biophys Acta, 1859, 46, 10.1016/j.bbagrm.2015.08.009
Ayupe, 2015, Global analysis of biogenesis, stability and sub-cellular localization of lncRNAs mapping to intragenic regions of the human genome, RNA Biol, 12, 877, 10.1080/15476286.2015.1062960
Cabili, 2015, Localization and abundance analysis of human lncRNAs at single-cell and single-molecule resolution, Genome Biol, 16, 20., 10.1186/s13059-015-0586-4
van Heesch, 2014, Extensive localization of long noncoding RNAs to the cytosol and mono- and polyribosomal complexes, Genome Biol, 15, R6., 10.1186/gb-2014-15-1-r6
Clark, 2012, Genome-wide analysis of long noncoding RNA stability, Genome Res, 22, 885, 10.1101/gr.131037.111
Poller, 2013, Cardiovascular RNA interference therapy: the broadening tool and target spectrum, Circ Res, 113, 588, 10.1161/CIRCRESAHA.113.301056
Lennox, 2016, Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides, Nucleic Acids Res, 44, 863, 10.1093/nar/gkv1206
Viereck, 2016, Long noncoding RNA Chast promotes cardiac remodeling, Sci Transl Med, 8, 326ra22., 10.1126/scitranslmed.aaf1475
Han, 2014, A long noncoding RNA protects the heart from pathological hypertrophy, Nature, 514, 102, 10.1038/nature13596
Ounzain, 2015, CARMEN, a human super enhancer-associated long noncoding RNA controlling cardiac specification, differentiation and homeostasis, J Mol Cell Cardiol, 89, 98, 10.1016/j.yjmcc.2015.09.016
Liu, 2014, Pathogenic role of lncRNA-MALAT1 in endothelial cell dysfunction in diabetes mellitus, Cell Death Dis, 5, e1506., 10.1038/cddis.2014.466
Gast, 2016, Long noncoding RNA MALAT1-derived mascRNA is involved in cardiovascular innate immunity, J Mol Cell Biol, 178
Peters, 2016, Long non-coding RNA MALAT-1 is dispensable during pressure overload-induced cardiac remodeling and failure in mice, PLoS One, 11, e0150236., 10.1371/journal.pone.0150236
Wu, 2014, LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity, Circulation, 130, 1452, 10.1161/CIRCULATIONAHA.114.011675
Kumarswamy, 2014, Circulating long noncoding RNA, LIPCAR, predicts survival in patients with heart failure, Circ Res, 114, 1569, 10.1161/CIRCRESAHA.114.303915
Ounzain, 2014, Genome-wide profiling of the cardiac transcriptome after myocardial infarction identifies novel heart-specific long non-coding RNAs, Eur Heart J, 36, 353, 10.1093/eurheartj/ehu180
Ounzain, 2014, Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease, J Mol Cell Cardiol, 76, 55, 10.1016/j.yjmcc.2014.08.009
Zhou, 2017, Aptamers as targeted therapeutics: current potential and challenges, Nat Rev Drug Discov, 16, 181, 10.1038/nrd.2016.199
Pinkert, 2009, Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor, Circulation, 120, 2358, 10.1161/CIRCULATIONAHA.108.845339
Nair, 2014, Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing, J Am Chem Soc, 136, 16958, 10.1021/ja505986a
Jones, 2016, Tackling breast cancer chemoresistance with nano-formulated siRNA, Gene Ther, 23, 821, 10.1038/gt.2016.67
Gao, 2002, Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy, Proc Natl Acad Sci U S A, 99, 11854, 10.1073/pnas.182412299
Gao, 2006, High-level transgene expression in nonhuman primate liver with novel adeno-associated virus serotypes containing self-complementary genomes, J Virol, 80, 6192, 10.1128/JVI.00526-06
Jessup, 2011, Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure, Circulation, 124, 304, 10.1161/CIRCULATIONAHA.111.022889
Bish, 2008, Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat, Hum Gene Ther, 19, 1359, 10.1089/hum.2008.123
Inagaki, 2006, Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8, Mol Ther, 14, 45, 10.1016/j.ymthe.2006.03.014
Pačak, 2006, Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo, Circ Res, 99, e3, 10.1161/01.RES.0000237661.18885.f6
Geisler, 2011, microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors, Gene Ther, 18, 199, 10.1038/gt.2010.141
Grimm, 2006, Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways, Nature, 441, 537, 10.1038/nature04791
Yang, 2009, A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection, Proc Natl Acad Sci U S A, 106, 3946, 10.1073/pnas.0813207106
Hamdani, 2013, Myocardial titin hypophosphorylation importantly contributes to heart failure with preserved ejection fraction in a rat metabolic risk model, Circ Heart Fail, 6, 1239, 10.1161/CIRCHEARTFAILURE.113.000539
Franssen, 2016, Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction, JACC Heart Fail, 4, 312, 10.1016/j.jchf.2015.10.007
Burnett, 2014, Running interference to lower cholesterol, Lancet, 383, 10, 10.1016/S0140-6736(13)61910-8
Bergeron, 2015, Proprotein convertase subtilisin/kexin type 9 inhibition: a new therapeutic mechanism for reducing cardiovascular disease risk, Circulation, 132, 1648, 10.1161/CIRCULATIONAHA.115.016080
Kho, 2011, SUMO1-dependent modulation of SERCA2a in heart failure, Nature, 477, 601, 10.1038/nature10407
Tilemann, 2013, SUMO-1 gene transfer improves cardiac function in a large-animal model of heart failure, Sci Transl Med, 5, 211ra159., 10.1126/scitranslmed.3006487
Haraguchi, 2009, Vectors expressing efficient RNA decoys achieve the long-term suppression of specific microRNA activity in mammalian cells, Nucleic Acids Res, 37, e43., 10.1093/nar/gkp040
Bak, 2013, Potent microRNA suppression by RNA Pol II-transcribed ‘Tough Decoy’ inhibitors, RNA, 19, 280, 10.1261/rna.034850.112
Hollensen, 2013, Suppression of microRNAs by dual-targeting and clustered Tough Decoy inhibitors, RNA Biol, 10, 406, 10.4161/rna.23543
Xie, 2012, Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma, Cancer, 118, 2431, 10.1002/cncr.26566
Sager, 2016, RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction, Sci Transl Med, 8, 342ra80., 10.1126/scitranslmed.aaf1435
Courties, 2014, In vivo silencing of the transcription factor IRF5 reprograms the macrophage phenotype and improves infarct healing, J Am Coll Cardiol, 63, 1556, 10.1016/j.jacc.2013.11.023
Leuschner, 2011, Therapeutic siRNA silencing in inflammatory monocytes in mice, Nat Biotechnol, 29, 1005, 10.1038/nbt.1989
Uchida, 2015, Long noncoding RNAs in cardiovascular diseases, Circ Res, 116, 737, 10.1161/CIRCRESAHA.116.302521
Navickas, 2016, Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review, Cardiovasc Res, 10.1093/cvr/cvw174
Danielson, 2017, High throughput sequencing of extracellular RNA from human plasma, PLoS One, 12, e0164644., 10.1371/journal.pone.0164644
Shah, 2016, Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs, PLoS One, 11, e0153200., 10.1371/journal.pone.0153200
Mitchell, 2008, Circulating microRNAs as stable blood-based markers for cancer detection, Proc Natl Acad Sci U S A, 105, 10513, 10.1073/pnas.0804549105
Wang, 2010, Circulating microRNA: a novel potential biomarker for early diagnosis of acute myocardial infarction in humans, Eur Heart J, 31, 659, 10.1093/eurheartj/ehq013
D'Alessandra, 2010, Circulating microRNAs are new and sensitive biomarkers of myocardial infarction, Eur Heart J, 31, 2765, 10.1093/eurheartj/ehq167
Olivieri, 2013, Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction, Int J Cardiol, 167, 531, 10.1016/j.ijcard.2012.01.075
Devaux, 2015, Diagnostic and prognostic value of circulating microRNAs in patients with acute chest pain, J Intern Med, 277, 260, 10.1111/joim.12183
Hoekstra, 2010, The peripheral blood mononuclear cell microRNA signature of coronary artery disease, Biochem Biophys Res Commun, 394, 792, 10.1016/j.bbrc.2010.03.075
Zeller, 2014, Assessment of microRNAs in patients with unstable angina pectoris, Eur Heart J, 35, 2106, 10.1093/eurheartj/ehu151
Meder, 2011, MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction, Basic Res Cardiol, 106, 13, 10.1007/s00395-010-0123-2
Vogel, 2013, Refining diagnostic microRNA signatures by whole-miRNome kinetic analysis in acute myocardial infarction, Clin Chem, 59, 410, 10.1373/clinchem.2011.181370
Piepoli, 2016, 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR), Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106
Ponikowski, 2016, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC, Eur J Heart Fail, 18, 891, 10.1002/ejhf.592
Widera, 2011, Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome, J Mol Cell Cardiol, 51, 872, 10.1016/j.yjmcc.2011.07.011
He, 2014, Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction, Mol Cell Biochem, 10.1007/s11010-014-2089-0
Zampetaki, 2012, Prospective study on circulating MicroRNAs and risk of myocardial infarction, J Am Coll Cardiol, 60, 290, 10.1016/j.jacc.2012.03.056
Kuehl, 2015, Differential cardiac microRNA expression predicts the clinical course in human enterovirus cardiomyopathy, Circ Heart Fail, 8, 605, 10.1161/CIRCHEARTFAILURE.114.001475
Kasner, 2016, Circulating exosomal microRNAs predict functional recovery after MitraClip repair of severe mitral regurgitation, Int J Cardiol, 215, 402, 10.1016/j.ijcard.2016.04.018
Morley-Smith, 2014, Circulating microRNAs for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device, Eur J Heart Fail, 16, 871, 10.1002/ejhf.116
Akat, 2014, Comparative RNA-sequencing analysis of myocardial and circulating small RNAs in human heart failure and their utility as biomarkers, Proc Natl Acad Sci U S A, 111, 11151, 10.1073/pnas.1401724111
Xiao, 2014, Decoding the noncoding transcripts in human heart failure, Circulation, 129, 958, 10.1161/CIRCULATIONAHA.114.007548
Matkovich, 2009, Reciprocal regulation of myocardial microRNAs and messenger RNA in human cardiomyopathy and reversal of the microRNA signature by biomechanical support, Circulation, 119, 1263, 10.1161/CIRCULATIONAHA.108.813576
El-Armouche, 2010, Common microRNA signatures in cardiac hypertrophic and atrophic remodeling induced by changes in hemodynamic load, PLoS One, 5, e14263., 10.1371/journal.pone.0014263
Corsten, 2010, Circulating MicroRNA-208b and MicroRNA-499 reflect myocardial damage in cardiovascular disease, Circ Cardiovasc Genet, 3, 499, 10.1161/CIRCGENETICS.110.957415
De Rosa, 2011, Transcoronary concentration gradients of circulating microRNAs, Circulation, 124, 1936, 10.1161/CIRCULATIONAHA.111.037572
Vausort, 2014, Long noncoding RNAs in patients with acute myocardial infarction, Circ Res, 115, 668, 10.1161/CIRCRESAHA.115.303836
Yang, 2015, Plasma long non-coding RNA, CoroMarker, a novel biomarker for diagnosis of coronary artery disease, Clin Sci (Lond), 129, 675, 10.1042/CS20150121
Cai, 2016, Circulating "LncPPARdelta" from monocytes as a novel biomarker for coronary artery diseases, Medicine (Baltimore), 95, e2360., 10.1097/MD.0000000000002360
Bayes-Genis, 2017, Transitioning from usual care to biomarker-based personalized and precision medicine in heart failure: call for action, Eur Heart J
Skroblin, 2014, "Going long": long non-coding RNAs as biomarkers, Circ Res, 115, 607, 10.1161/CIRCRESAHA.114.304839
Memczak, 2015, Identification and characterization of circular RNAs as a new class of putative biomarkers in human blood, PLoS One, 10, e0141214., 10.1371/journal.pone.0141214
Boeckel, 2015, Identification and Characterization of hypoxia-regulated endothelial circular RNA, Circ Res, 117, 884, 10.1161/CIRCRESAHA.115.306319
Li, 2015, Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis, Cell Res, 25, 981, 10.1038/cr.2015.82
Backes, 2015, Influence of next-generation sequencing and storage conditions on miRNA patterns generated from PAXgene blood, Anal Chem, 87, 8910, 10.1021/acs.analchem.5b02043
Chen, 2008, Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases, Cell Res, 18, 997, 10.1038/cr.2008.282
Cai, 2016, Circulating ‘lncRNA OTTHUMT00000387022’ from monocytes as a novel biomarker for coronary artery disease, Cardiovasc Res, 10.1093/cvr/cvw022
Weber, 2011, MicroRNA expression profile in CAD patients and the impact of ACEI/ARB, Cardiol Res Pract, 2011, 532915., 10.4061/2011/532915
Boeckel, 2013, Heparin selectively affects the quantification of microRNAs in human blood samples, Clin Chem, 59, 1125, 10.1373/clinchem.2012.199505
Gidlof, 2011, Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with ST elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples, Cardiology, 118, 217, 10.1159/000328869
Meder, 2014, Influence of the confounding factors age and sex on microRNA profiles from peripheral blood, Clin Chem, 60, 1200, 10.1373/clinchem.2014.224238
Hantzsch, 2014, Comparison of whole blood RNA preservation tubes and novel generation RNA extraction kits for analysis of mRNA and MiRNA profiles, PLoS One, 9, e113298., 10.1371/journal.pone.0113298
Schwarzenbach, 2015, Data normalization strategies for MicroRNA quantification, Clin Chem, 61, 1333, 10.1373/clinchem.2015.239459
Lyman, 2016, Biomarker tests for molecularly targeted therapies—the key to unlocking precision medicine, N Engl J Med, 375, 4, 10.1056/NEJMp1604033